Celldex Therapeutics (CLDX) Free Cash Flow (2010 - 2026)

Celldex Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$67.2 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 23.06% year-over-year to -$67.2 million; the TTM figure through Mar 2026 stood at -$226.3 million (down 30.52% YoY), while the FY2025 annual figure was -$213.7 million, down 33.79% from the prior year.
• Free Cash Flow was -$67.2 million for Q1 2026 at Celldex Therapeutics, down from -$65.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$19.2 million in Q3 2023 to a low of -$67.2 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$38.5 million across 5 years, with a median of -$33.2 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow jumped 46.11% in 2023, then sank 191.81% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$22.0 million in 2022, then plunged by 50.93% to -$33.2 million in 2023, then slipped by 0.1% to -$33.2 million in 2024, then slumped by 96.26% to -$65.2 million in 2025, then declined by 3.09% to -$67.2 million in 2026.
• The last three Free Cash Flow figures came in at -$67.2 million (Q1 2026), -$65.2 million (Q4 2025), and -$49.0 million (Q3 2025), per Business Quant data.